Could be, but they have not bought drugs in the past as Fresnius has. They are aware of the value of the asset. They have already written articles on the potential savings that Zerenex could generate. I would think a product license agreement would make more sense for DaVita; and I think Keryx's recently hired CMO is the perfect guy to make that happen given his knowledge and relationships with the dialysis centers. What I don't know is whether that is a deal that gets struck pre-approval or not. .
For my money, I think the smartest buyer is Sanofi. They have all of the current infrastructure in place -- all the relationships with the distribution channels, and given their market penetration both here in the US and abroad, unique and very deep access to the end user population. They also have a drug that is facing certain price competition from generics and price pressure from bundling. They have the capital base to quickly gear up manufacturing capacity, and to me it is a smart way to protect and enhance a valuable franchise whose value will diminish from the combined pressure of generics, bundling and Zerenex if they do nothing. Acquiring Z is really their only way to protect that franchise, and they have the ability and resources to immediately achieve scale. Talk about "plug and play"! Add in the CKD opportunity and it is a purchase that will allow them to expand their franchise Vs watching it disappear. Let's hope there are other parties who don't want Sanofi to get such a clear competitive edge!